Big Stakes In Lilly Patent Battle: How Broadly Can Patent Claims Be Written?
As Lilly and Ariad get back in the ring for another round in a major patent battle, those on the sidelines are closely watching the match as it could determine how broadly patent claims may be written. At issue is the question of what constitutes an adequate description of an invention
You may also be interested in...
An appeals court ruling that limits the patenting of DNA sequences could have negative repercussions for the industry
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.